enGene
Alex Nichols is an accomplished biotechnology executive with extensive experience in leadership roles. Currently serving as the President and Chief Operating Officer at enGene since January 2023, Alex previously co-founded and led Mythic Therapeutics as President and CEO from April 2017 to August 2022. Alex's venture-building expertise includes co-founding Cogen Therapeutics and offering strategic consulting through Crown Line Consulting, LLC. Educationally, Alex holds a PhD in Biophysics from Harvard University and has been recognized with prestigious fellowships, including the National Defense Science and Engineering Graduate Fellowship and the National Science Foundation Graduate Research Fellowship. Early career experience includes a role as Staff Chemist at QD Vision, Inc., focusing on semiconductor nanocrystal development.
This person is not in any teams
This person is not in any offices
enGene
enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications